Twist Bioscience (TWST) Cash & Equivalents (2018 - 2026)

Twist Bioscience (TWST) has reported Cash & Equivalents for 9 consecutive years, with $117.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 41.69% year-over-year to $117.4 million in Q2 2026; TTM through Jun 2026 was $117.4 million, a 41.69% decrease from a year earlier, with the FY2025 full-year figure at $183.0 million, down 19.12% from the prior year.
• Cash & Equivalents was $117.4 million for Q2 2026 at Twist Bioscience, down from $122.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $407.6 million in Q1 2022 and troughed at $117.4 million in Q2 2026.
• A 5-year average of $253.8 million and a median of $241.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 65.26% in 2022 and tumbled 41.69% in 2026, its largest moves.
• Over 5 years, Cash & Equivalents stood at $316.7 million in 2022, then slipped by 15.92% to $266.3 million in 2023, then dropped by 16.85% to $221.4 million in 2024, then sank by 32.88% to $148.6 million in 2025, then fell by 20.97% to $117.4 million in 2026.
• The last three Cash & Equivalents figures came in at $117.4 million (Q2 2026), $122.7 million (Q1 2026), and $148.6 million (Q4 2025), per Business Quant data.